Ljubljana/methods

From 2007.igem.org

(Difference between revisions)
Line 4: Line 4:
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1" />
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1" />
<link href="http://rokgaber.3host.biz/stylenew_zadaj.css" rel="stylesheet" type="text/css" />
<link href="http://rokgaber.3host.biz/stylenew_zadaj.css" rel="stylesheet" type="text/css" />
-
</head>
 
-
<body>
 
-
<div id="container">
+
 
-
  <div id="intro">
+
-
    <div id="pageHeader">
+
   
   
-
 
-
 
-
   
 
-
    </div>
 
-
   
 
-
  </div>
 
-
 
-
 
-
 
-
 
-
 
-
 
-
  <div id="supportingText">
 
-
 
-
 
-
 
-
 
-
<div id="products">
 
-
      <h3><span>Parts Design</span></h3>
 
-
      <p class="p1"><span>Since almost all of the parts used by our team had to be designed <i>de novo</i>, a huge portion of our time in the lab was spent on cloning. For each basic part, we designed primers containing standard BioBrick restriction sites. We had to introduce point mutations into some genes, because they contained one or more standard restriction sites inside the coding region. These mutations were introduced by PCR-driven overlap extension method <font color="red">(REFERENCA)</font>.<br>
 
-
The genes, amplified by PCR, were therefore flanked by <i>Xba</i>I site upstream and <i>Spe</i>I, <i>Not</i>I and <i>Pst</i>I downstream of the gene. After restriction, fragments were cloned into <a href="http://partsregistry.org/Part:BBa_J52017">BBa_J52017</a>, a vector already containing a eukaryotic terminator sequence downstream of the cloning region. This vector has previously been constructed by the Slovenian iGEM 2006 team.<br>
 
-
In addition to basic parts, we also designed dozens of composite parts, mainly constructs expressing chimeric proteins. Composite parts were assembled by three-point ligations <font color="red">(REFERENCA)</font>, leaving 6 nucleotides long <i>Spe</i>I-<i>Xba</i>I mixed restriction site inbetween the two domains. Some of our composite parts contain as many as 6 basic parts. Such composite parts were constructed by repeating three point ligations.<br><br>
 
-
 
-
</a></span></p><br>
 
-
 
-
 
-
 
-
 
-
     
 
-
      <h3><span>Current Disease Treatment</span></h3>
 
-
      <p class="p1">One of the first AIDS therapeutics were nucleotide or nucleoside analogues (NRTI – nucleoside-analogue reverse transcriptase inhibitors) – pseudosubstrates, that are during reverse transcription integrated into viral DNA instead of nucleosides and thus block the transcription. These drugs were superseded by non-nucleoside inhibitors (NNRTI) that could inhibit reverse transcriptase by binding into the alosteric site of the enzyme. The third type of drugs is a family of HIV protease inhibitors. In most cases specific inhibitors are very similar to protease substrates - the only difference is that because they cannot be cut, they block the active site by remaining bound into it.<br><br>
 
-
 
-
Weakness of all these therapeutics is that they are very sensitive to HIV mutations – HIV can easily mutate and thus become drug resistant. A combination of drugs is used to minimize HIV's potential to develop resistance to each individual drug in the mixture. Some of the drugs induce mutations that have negative effect on the virulence and such drugs can be used in spite of developed resistance.<br><br>
 
-
 
-
We still do not have a cure for AIDS that would be insensitive to HIV mutations. Our project presents new ways of potential AIDS therapeutics. Our approaches can be considered independent of HIV mutations. We have set up a few of biological ambushes; if HIV manages to avoid them, we presume that it would not be able to infect the cell anyway.</p>
 
-
 
-
 
-
   
 
-
    </div>
 
-
 
-
 
-
 
-
    <div id="support">
 
-
      <h3><span>Classes of Antiretroviral Drugs</span></h3>
 
-
      <p class="p1">Antiretroviral drugs are mostly inhibitors of different stages in HIV life cycle. They are targeted at different enzymes or events that are typical for HIV infection – entry of the virus into the cell, reverse transcription, polyprotein cleavage... and are divided into seven main classes (REFERENCA!):<br>
 
-
 
-
 
-
 
-
 
-
 
-
</p>
 
-
    </div>
 
-
 
-
 
-
 
-
    <div id="development">
 
-
      <h3><span>Development</span></h3>
 
-
      <p class="p1">Lorem ipsum dolor sit amet, <a href="#">consetetur sadipscing elitr, sed diam nonumy</a> eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. </p>
 
-
      <p class="p2">Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. </p>
 
-
      <p class="p3">Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. </p>
 
-
      <p class="p4">Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. </p>
 
-
      <p class="p5">Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore.</p>
 
-
    </div>
 

Revision as of 21:12, 25 October 2007

Company Name